UNH has taken a beating recently (-19% drop), sitting around $282. The narrative is scary (Medicare rates, revenue decline), but I wanted to strip away the emotion and look at the intrinsic value.
I treat UNH as a "Distressed Cash Cow," so I avoided standard growth models and focused on dividend safety and earnings power. Here is the breakdown:
**The Data**
* **Price:** \~$282
* **2026 EPS Est:** \~$17.75 (Management Guidance)
* **Yield:** \~3.1% (Historic high)
* **Safety:** Net Debt/EBITDA is 1.7x (Safe)
**The 4 Valuation Models**
1. **Fair P/E (De-rated):** Historically trades at 20x+. I assumed a permanent compression to **16-17x** due to regulatory headwinds. -> **Value: $302**
2. **Conservative DCF:** Assumed 8% growth (below historic 14%) for 5 years. -> **Value: $295**
3. **Dividend Discount Model (DDM):** With the yield over 3%, this is now an income play. Assuming 6% div growth. -> **Value: $295**
4. **FCF Yield:** Market demanding a 5.5% yield for the risk. -> **Value: $314**
**The Verdict**
* **True Intrinsic Value:** \~$301
* **Current Discount:** \~6%
**My Take:** UNH is efficiently priced for a "low growth" environment. It is roughly Fair Value here, but it isn't a screaming bargain (I'd need <$240 for a 20% Margin of Safety). It's a "hold your nose and buy" for the dividend, but the compounder thesis is on pause until revenue stabilizes.
Is anyone else buying here, or is the Medicare risk too structural this time?